Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II ECP plus high-dose steroids for high-risk acute GvHD
2019-000894-22Phase 2Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Oct 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methoxsalen and methylprednisolone in graft-versus-host disease (GVHD), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Day 28 complete response rate. Started Oct 2019; status: completed.
02
Drugs
methoxsalenmethylprednisolone
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on 2019-000894-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000894-22.